Proteomics International Laboratories receives R&D Tax Incentive

Life sciences company Proteomics International Laboratories Ltd (ASX: PIQ) (the Company, PILL) is pleased to announce it has received an Australian Government R&D Tax Incentive payment of $309,010 for the year ending 30 June 2015.

The Company received the R&D Tax Incentive after spending in excess of $700,000 on R&D activities within its world leading proteomics-focused business in the 2014-15 financial year.

The funds from the R&D Tax Incentive will complement PILL’s existing cash reserves and be used to continue to advance the application and commercialisation of the Company’s products and services derived from its proteomics-based technology platform.

Proteomics is the industrial scale study of the structure and function of proteins and PILL is recognised as a global leader in its field.

The R&D Tax Incentive is administered by the Australian Department of Industry and Science, and is designed to provide a targeted tax offset to encourage companies to engage in research and development.

ENDS

For further information please contact:
Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Greg Wood [Financial Advisor]
Managing Director
K S Capital
T: +61 416 076 377
E: g.wood@kscapital.com.au

For personal use only
Part of the PILL Group
About Proteomics International Laboratories

PILL is an ASX listed (ASX: PIQ) life science company focused on the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics is an integral part of the biotechnology and life sciences industries and plays a key role in understanding disease and biological systems.

PILL is recognised as a global leader in its field. It received the world’s first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. The Company’s business model uses its proprietary technology platform which operates across three synergistic proteomics-based business units in massive growth markets:

1. **Diagnostics**: Biomarkers of diseases and personalised medicine - focus on diabetic kidney disease and Alzheimer’s disease. The biomarkers market is estimated to double in size to $45.6 billion by 2020.
2. **Analytical services**: Specialist contract research, analytical testing and consultancy - fee for service model. The specialist proteomics market alone represents a massive global market estimated to be worth $20.8 billion by 2018.
3. **Drug discovery**: Therapeutic drug discovery with a focus on painkillers and antibiotics. The peptide therapeutics market is currently estimated to be worth $17 billion.